Allied CorpOTCQB:ALID
- LAST PRICE0.1900
- TODAY'S CHANGE (%)0.0450 (31.0345%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.1739 / 0.1450
- Day Range
- 52 Week Range
- Volume25,200
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALID |
|---|---|---|
| 09:45 ET | 20957 | 0.189 |
| 12:21 ET | 3100 | 0.2 |
| 12:38 ET | 1143 | 0.19 |
Apr 4, 2024
Allied Corp Completes 80kg Shipment to European Channel Partner Coinciding with German Decriminalization Act, from 3:00PM ET on Thursday Apr 04, 2024 by Dow Jones
3:00PM ET on Thursday Apr 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Allied Corp | 15.3M | -1.8x | --- |
Cocrystal Pharma Inc | 15.9M | -0.8x | --- |
Talphera Inc | 16.1M | -1.3x | --- |
Sentient Brands Holdings Inc | 5.5M | -12.8x | --- |
TherapeuticsMD Inc | 21.7M | -2.6x | --- |
Resonate Blends Inc | 3.4M | -2.0x | --- |
Company Information
Allied Corp. is an international medical cannabis production company. The Company is focused on the development of medicinal cannabis and psilocybin products for patients with conditions potentially suitable for treatment there with. Such conditions include anxiety, insomnia, anorexia, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, post-traumatic stress disorder (PTSD), Parkinson’s disease, Tourette syndrome, irritable bowel syndrome (IBS) and spasticity associated with multiple sclerosis (MS) and spinal cord injury (SCI)1. Its wholly owned subsidiaries include AM Biosciences, Allied US Products LLC, Tactical Relief LLC, Baleno Ltd., and Allied Colombia.
Contact Information
- Headquarters
- SUITE 200-460 DOYLE AVEKELOWNA, BC, Canada V1Y OC2
- Phone
- 778-388-5258
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Calum Hughes
- Chief Financial Officer
- Ryan Maarschalk
- Chief Operating Officer, Director
- Paul Bullock
- Vice President of Pharmaceuticals and Director
- Jim Smeeding
- Vice President - Corporate Development
- Santiago Ribero
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.3M |
|---|---|
Revenue (TTM) | $21.5K |
Shares Outstanding | 105.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.61 |
EPS | $-0.10 |
Book Value | $-0.07 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | 713.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -45,595.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
